Subjective effects of cannabis before the first psychotic episode

References

• Moore TH, Zammit S, Lingford-Hughes A. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370:(9584):319–328.
   PubMed Web of Science ®Google Scholar
• Brook D, Brook J, Zhang C, Cohen P, Whiteman M. Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch Gen Psychiatry 2002; 59:1039–1044.
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ. The Christchurch Health and Development Study: review of findings on child and adolescent mental health. Aust N Z J Psychiatry 2001; 35:287–296.
   PubMed Web of Science ®Google Scholar
• Pope HG, Jr Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69:303–310.
   PubMed Web of Science ®Google Scholar
• O’Shea M, Singh ME, McGregor IS, Mallet PE. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 2004; 18:502–508.
   PubMed Web of Science ®Google Scholar
• Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003; 28:1760–1769.
   PubMed Web of Science ®Google Scholar
• Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 2003; 98:685–692.
   PubMed Web of Science ®Google Scholar
• Keshavan MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res 1999; 33:513–521.
   PubMed Web of Science ®Google Scholar
• Schofield D, Tennant C, Nash L, . Reasons for cannabis use in psychosis. Aust N Z J Psychiatry 2006; 40:570–574.
   PubMed Web of Science ®Google Scholar
• Green B, Kavanagh DJ, Young RM. Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev 2004; 23:445–453.
   PubMed Web of Science ®Google Scholar
• Addington J, Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatr Scand 1997; 96:329–333.
   PubMed Web of Science ®Google Scholar
• Baigent M, Holme G, Hafner RJ. Self reports of the interaction between substance abuse and schizophrenia. Aust N Z J Psychiatry 1995; 29:69–74.
   PubMed Web of Science ®Google Scholar
• Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991; 148:224–230.
   PubMed Web of Science ®Google Scholar
• Test MA, Wallisch LS, Allness DJ, Ripp K. Substance use in young adults with schizophrenic disorders. Schizophr Bull 1989; 15:465–476.
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Abi-Saab WM, Madonick S, . Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57:594–608.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association DSM-IV: Diagnostic and statistical manual of mental disorders. 4th edn. Washington DC: American Psychiatric Association, 1994.
   Google Scholar
• Spitzer RL, Williams JBW. Classification of mental disorders. Kaplan HJ, Sadock BJ, Comprehensive textbook of psychiatry. 4th edn. Baltimore MD: Williams and Wilkins, 1985; 591–612.
   Google Scholar
• Klosterkötter J, Ruhrmann S, Schultze-Lutter F, . The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry 2005; 4:161–167.
   PubMedGoogle Scholar
• Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58:158–164.
   PubMed Web of Science ®Google Scholar
• Boys A, Marsden J, Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res 2001; 16:457–469.
   PubMed Web of Science ®Google Scholar
• Häfner H, Riecher-Rossler A, Hambrecht M, . IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res 1992; 6:209–223.
   PubMed Web of Science ®Google Scholar
• Pope HG Jr, Gruber AJ, Yurgelun-Todd D. The residual neuro-psychological effects of cannabis: the current status of research. Drug Alcohol Depend 1995; 38:25–34.
   PubMed Web of Science ®Google Scholar
• Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158:2033–2037.
   PubMed Web of Science ®Google Scholar
• Musty RE, Kaback L. Relationships between motivation and depression in chronic marijuana users. Life Sci 1995; 56:2151–2158.
   PubMed Web of Science ®Google Scholar
• Cannon TD, Cadenhead K, Cornblatt B, . Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65:28–37.
   PubMed Web of Science ®Google Scholar
• Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2001; 36:338–342.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 2007; 151:151–154.
   PubMed Web of Science ®Google Scholar
• Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. Cannabis use is not associated with the development of psychosis in an ‘ultra’ high-risk group. Aust N Z J Psychiatry 2002; 36:800–806.
   PubMed Web of Science ®Google Scholar
• Linszen D, van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry 2007; 20:116–120.
   PubMed Web of Science ®Google Scholar
• Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001; 107:173–177.
   PubMed Web of Science ®Google Scholar
• Henquet C, Rosa A, Krabbendam L, . An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006; 31:2748–2757.
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE, Cannon M . Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57:1117–1127.
   PubMed Web of Science ®Google Scholar
• Holden RJ, Pakula I. Marijuana, stress and suicide: a neuroimmuno-logical explanation. Aust N Z J Psychiatry 1998; 32:465–466.
   PubMed Web of Science ®Google Scholar
• Jentsch JD, Verrico CD, Le D, Roth RH. Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neurosci Lett 1998; 246:169–172.
   PubMed Web of Science ®Google Scholar
• Verrico CD, Jentsch JD, Roth RH. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 2003; 49:61–66.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Lejeune F, Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 2000; 14:114–138.
   PubMed Web of Science ®Google Scholar
• Mangieri RA, Piomelli D. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res 2007; 56:360–366.
   PubMed Web of Science ®Google Scholar
• Müller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 2008; 8:1037–1048.
   PubMedGoogle Scholar
• Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44:660–669.
   PubMed Web of Science ®Google Scholar
• Coulston CM, Perdices M, Tennant CC. The neuropsycho-logical correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophr Res 2007; 96:169–184.
   PubMed Web of Science ®Google Scholar
• Marco EM, Pérez-Alvarez L, Borcel E, . Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 2004; 15:21–27.
   PubMed Web of Science ®Google Scholar
• Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005; 81:331–342.
   PubMed Web of Science ®Google Scholar
• Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007; 192:61–70.
   PubMed Web of Science ®Google Scholar
• Arendt M, Rosenberg R, Fjordback L, . Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects. Psychol Med 2007; 37:935–945.
   PubMed Web of Science ®Google Scholar
• Bortolato M, Mangieri RA, Fu J, . Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007; 62:1103–1110.
   PubMed Web of Science ®Google Scholar
• Häfner H, Loffler W, Maurer K, Hambrecht M, van der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 1999; 100:105–118.
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003; 9:404–416.
   PubMed Web of Science ®Google Scholar
• Diana M, Melis M, Gessa GL. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 1998; 10:2825–2830.
   PubMed Web of Science ®Google Scholar
• Martin G, Copeland J. The adolescent cannabis check-up: randomized trial of a brief intervention for young cannabis users. J Subst Abuse Treat 2008; 34:407–414.
   PubMed Web of Science ®Google Scholar
• Wolkind S, Coleman EZ. Adult psychiatric disorder and childhood experiences. The validity of retrospective data. Br J Psychiatry 1983; 143:188–191.
   PubMed Web of Science ®Google Scholar
• Pope HG, Jr. Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58:909–915.
   PubMed Web of Science ®Google Scholar